Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 207

1.

Spontaneous murine tumors in the development of patient-derived xenografts: a potential pitfall.

Moyer AM, Yu J, Sinnwell JP, Dockter TJ, Suman VJ, Weinshilboum RM, Boughey JC, Goetz MP, Visscher DW, Wang L.

Oncotarget. 2019 Jun 11;10(39):3924-3930. doi: 10.18632/oncotarget.27001. eCollection 2019 Jun 11.

2.

Tamoxifen Metabolism and Breast Cancer Recurrence: A Question Unanswered by CYPTAM.

Goetz MP, Suman VJ, Nakamura Y, Kiyotani K, Jordan VC, Ingle JN.

J Clin Oncol. 2019 Aug 1;37(22):1982-1983. doi: 10.1200/JCO.19.00504. Epub 2019 Jun 18. No abstract available.

PMID:
31211604
3.

Should Overall Survival Remain an Endpoint for Multiple Myeloma Trials?

Holstein SA, Suman VJ, McCarthy PL.

Curr Hematol Malig Rep. 2019 Feb;14(1):31-38. doi: 10.1007/s11899-019-0495-9. Review.

PMID:
30661162
4.

Commentary on "Is posttransplant lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma" by Giovanni Barosi and Robert Peter Gale.

Holstein SA, Suman VJ, McCarthy PL.

Leukemia. 2019 Feb;33(2):565-566. doi: 10.1038/s41375-018-0359-7. Epub 2019 Jan 11. No abstract available.

PMID:
30635635
5.

ERβ-mediated induction of cystatins results in suppression of TGFβ signaling and inhibition of triple-negative breast cancer metastasis.

Reese JM, Bruinsma ES, Nelson AW, Chernukhin I, Carroll JS, Li Y, Subramaniam M, Suman VJ, Negron V, Monroe DG, Ingle JN, Goetz MP, Hawse JR.

Proc Natl Acad Sci U S A. 2018 Oct 9;115(41):E9580-E9589. doi: 10.1073/pnas.1807751115. Epub 2018 Sep 26.

6.

Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy: The ACOSOG Z1041 (Alliance) Randomized Clinical Trial.

Buzdar AU, Suman VJ, Meric-Bernstam F, Leitch AM, Ellis MJ, Boughey JC, Unzeitig GW, Royce ME, Hunt KK.

JAMA Oncol. 2019 Jan 1;5(1):45-50. doi: 10.1001/jamaoncol.2018.3691.

7.

Patterns of failure following the excision of in-transit lesions in melanoma and the influence of excisional margins.

Gonzalez AB, Baum CL, Brewer JD, Arpey CJ, Harmsen WS, Suman VJ, Markovic SN, Jakub JW.

J Surg Oncol. 2018 Sep;118(4):606-613. doi: 10.1002/jso.25176. Epub 2018 Aug 16.

8.

Non-invasive visualization of tumor infiltrating lymphocytes in patients with metastatic melanoma undergoing immune checkpoint inhibitor therapy: a pilot study.

Markovic SN, Galli F, Suman VJ, Nevala WK, Paulsen AM, Hung JC, Gansen DN, Erickson LA, Marchetti P, Wiseman GA, Signore A.

Oncotarget. 2018 Jul 13;9(54):30268-30278. doi: 10.18632/oncotarget.25666. eCollection 2018 Jul 13.

9.

Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer.

Lei JT, Shao J, Zhang J, Iglesia M, Chan DW, Cao J, Anurag M, Singh P, He X, Kosaka Y, Matsunuma R, Crowder R, Hoog J, Phommaly C, Goncalves R, Ramalho S, Peres RMR, Punturi N, Schmidt C, Bartram A, Jou E, Devarakonda V, Holloway KR, Lai WV, Hampton O, Rogers A, Tobias E, Parikh PA, Davies SR, Li S, Ma CX, Suman VJ, Hunt KK, Watson MA, Hoadley KA, Thompson EA, Chen X, Kavuri SM, Creighton CJ, Maher CA, Perou CM, Haricharan S, Ellis MJ.

Cell Rep. 2018 Aug 7;24(6):1434-1444.e7. doi: 10.1016/j.celrep.2018.07.009.

10.

Update on the role of lenalidomide in patients with multiple myeloma.

Holstein SA, Suman VJ, McCarthy PL.

Ther Adv Hematol. 2018 Jul;9(7):175-190. doi: 10.1177/2040620718775629. Epub 2018 May 26. Review.

11.

Comprehensive annotation of BRCA1 and BRCA2 missense variants by functionally validated sequence-based computational prediction models.

Hart SN, Hoskin T, Shimelis H, Moore RM, Feng B, Thomas A, Lindor NM, Polley EC, Goldgar DE, Iversen E, Monteiro ANA, Suman VJ, Couch FJ.

Genet Med. 2019 Jan;21(1):71-80. doi: 10.1038/s41436-018-0018-4. Epub 2018 Jun 8.

12.

DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine.

Yu J, Qin B, Moyer AM, Nowsheen S, Liu T, Qin S, Zhuang Y, Liu D, Lu SW, Kalari KR, Visscher DW, Copland JA, McLaughlin SA, Moreno-Aspitia A, Northfelt DW, Gray RJ, Lou Z, Suman VJ, Weinshilboum R, Boughey JC, Goetz MP, Wang L.

J Clin Invest. 2018 Jun 1;128(6):2376-2388. doi: 10.1172/JCI97924. Epub 2018 Apr 30.

13.

Phase II Study of Everolimus in Metastatic Malignant Melanoma (NCCTG-N0377, Alliance).

Vera Aguilera J, Rao RD, Allred JB, Suman VJ, Windschitl HE, Kaur JS, Maples WJ, Lowe VJ, Creagan ET, Erickson LA, Markovic S.

Oncologist. 2018 Aug;23(8):887-e94. doi: 10.1634/theoncologist.2018-0100. Epub 2018 Apr 17.

14.

Comparison of a Medical-Grade Monitor vs Commercial Off-the-Shelf Display for Mitotic Figure Enumeration and Small Object (Helicobacter pylori) Detection.

Norgan AP, Suman VJ, Brown CL, Flotte TJ, Mounajjed T.

Am J Clin Pathol. 2018 Jan 29;149(2):181-185. doi: 10.1093/ajcp/aqx154.

PMID:
29365023
15.

ERβ inhibits cyclin dependent kinases 1 and 7 in triple negative breast cancer.

Reese JM, Bruinsma ES, Monroe DG, Negron V, Suman VJ, Ingle JN, Goetz MP, Hawse JR.

Oncotarget. 2017 Oct 11;8(57):96506-96521. doi: 10.18632/oncotarget.21787. eCollection 2017 Nov 14.

16.

Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study.

Yu J, Qin B, Moyer AM, Sinnwell JP, Thompson KJ, Copland JA 3rd, Marlow LA, Miller JL, Yin P, Gao B, Minter-Dykhouse K, Tang X, McLaughlin SA, Moreno-Aspitia A, Schweitzer A, Lu Y, Hubbard J, Northfelt DW, Gray RJ, Hunt K, Conners AL, Suman VJ, Kalari KR, Ingle JN, Lou Z, Visscher DW, Weinshilboum R, Boughey JC, Goetz MP, Wang L.

Breast Cancer Res. 2017 Dec 6;19(1):130. doi: 10.1186/s13058-017-0920-8.

17.

A comprehensive analysis of breast cancer microbiota and host gene expression.

Thompson KJ, Ingle JN, Tang X, Chia N, Jeraldo PR, Walther-Antonio MR, Kandimalla KK, Johnson S, Yao JZ, Harrington SC, Suman VJ, Wang L, Weinshilboum RL, Boughey JC, Kocher JP, Nelson H, Goetz MP, Kalari KR.

PLoS One. 2017 Nov 30;12(11):e0188873. doi: 10.1371/journal.pone.0188873. eCollection 2017.

18.

Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer.

Doostan I, Karakas C, Kohansal M, Low KH, Ellis MJ, Olson JA Jr, Suman VJ, Hunt KK, Moulder SL, Keyomarsi K.

Clin Cancer Res. 2017 Dec 1;23(23):7288-7300. doi: 10.1158/1078-0432.CCR-17-1544. Epub 2017 Sep 25.

19.

First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer.

Goetz MP, Suman VJ, Reid JM, Northfelt DW, Mahr MA, Ralya AT, Kuffel M, Buhrow SA, Safgren SL, McGovern RM, Black J, Dockter T, Haddad T, Erlichman C, Adjei AA, Visscher D, Chalmers ZR, Frampton G, Kipp BR, Liu MC, Hawse JR, Doroshow JH, Collins JM, Streicher H, Ames MM, Ingle JN.

J Clin Oncol. 2017 Oct 20;35(30):3391-3400. doi: 10.1200/JCO.2017.73.3246. Epub 2017 Aug 30.

20.

Phase II trial of pazopanib in advanced/progressive malignant pheochromocytoma and paraganglioma.

Jasim S, Suman VJ, Jimenez C, Harris P, Sideras K, Burton JK, Worden FP, Auchus RJ, Bible KC.

Endocrine. 2017 Aug;57(2):220-225. doi: 10.1007/s12020-017-1359-5. Epub 2017 Jul 6.

PMID:
28685225
21.

Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy-results from the ACOSOG Z1041 (Alliance) trial.

Lesurf R, Griffith OL, Griffith M, Hundal J, Trani L, Watson MA, Aft R, Ellis MJ, Ota D, Suman VJ, Meric-Bernstam F, Leitch AM, Boughey JC, Unzeitig G, Buzdar AU, Hunt KK, Mardis ER.

Ann Oncol. 2017 May 1;28(5):1070-1077. doi: 10.1093/annonc/mdx048.

22.

Tumor Sequencing and Patient-Derived Xenografts in the Neoadjuvant Treatment of Breast Cancer.

Goetz MP, Kalari KR, Suman VJ, Moyer AM, Yu J, Visscher DW, Dockter TJ, Vedell PT, Sinnwell JP, Tang X, Thompson KJ, McLaughlin SA, Moreno-Aspitia A, Copland JA, Northfelt DW, Gray RJ, Hunt K, Conners A, Sicotte H, Eckel-Passow JE, Kocher JP, Ingle JN, Ellingson MS, McDonough M, Wieben ED, Weinshilboum R, Wang L, Boughey JC.

J Natl Cancer Inst. 2017 Jul 1;109(7). doi: 10.1093/jnci/djw306.

23.

Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).

Ellis MJ, Suman VJ, Hoog J, Goncalves R, Sanati S, Creighton CJ, DeSchryver K, Crouch E, Brink A, Watson M, Luo J, Tao Y, Barnes M, Dowsett M, Budd GT, Winer E, Silverman P, Esserman L, Carey L, Ma CX, Unzeitig G, Pluard T, Whitworth P, Babiera G, Guenther JM, Dayao Z, Ota D, Leitch M, Olson JA Jr, Allred DC, Hunt K.

J Clin Oncol. 2017 Apr 1;35(10):1061-1069. doi: 10.1200/JCO.2016.69.4406. Epub 2017 Jan 3.

24.

Safety and Feasibility of Minimally Invasive Inguinal Lymph Node Dissection in Patients With Melanoma (SAFE-MILND): Report of a Prospective Multi-institutional Trial.

Jakub JW, Terando AM, Sarnaik A, Ariyan CE, Faries MB, Zani S Jr, Neuman HB, Wasif N, Farma JM, Averbook BJ, Bilimoria KY, Grotz TE, Allred JB, Suman VJ, Brady MS, Tyler D, Wayne JD, Nelson H.

Ann Surg. 2017 Jan;265(1):192-196. doi: 10.1097/SLA.0000000000001670.

25.

Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511).

Freedman RA, Seisler DK, Foster JC, Sloan JA, Lafky JM, Kimmick GG, Hurria A, Cohen HJ, Winer EP, Hudis CA, Partridge AH, Carey LA, Jatoi A, Klepin HD, Citron M, Berry DA, Shulman LN, Buzdar AU, Suman VJ, Muss HB.

Breast Cancer Res Treat. 2017 Jan;161(2):363-373. doi: 10.1007/s10549-016-4051-1. Epub 2016 Nov 19.

26.

Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers.

Miller CA, Gindin Y, Lu C, Griffith OL, Griffith M, Shen D, Hoog J, Li T, Larson DE, Watson M, Davies SR, Hunt K, Suman VJ, Snider J, Walsh T, Colditz GA, DeSchryver K, Wilson RK, Mardis ER, Ellis MJ.

Nat Commun. 2016 Aug 9;7:12498. doi: 10.1038/ncomms12498.

27.

Aberrant Glycosylation of Anchor-Optimized MUC1 Peptides Can Enhance Antigen Binding Affinity and Reverse Tolerance to Cytotoxic T Lymphocytes.

Pathangey LB, Lakshminarayanan V, Suman VJ, Pockaj BA, Mukherjee P, Gendler SJ.

Biomolecules. 2016 Jun 29;6(3). pii: E31. doi: 10.3390/biom6030031.

28.

Clonal expansion of antitumor T cells in breast cancer correlates with response to neoadjuvant chemotherapy.

Park JH, Jang M, Tarhan YE, Katagiri T, Sasa M, Miyoshi Y, Kalari KR, Suman VJ, Weinshilboum R, Wang L, Boughey JC, Goetz MP, Nakamura Y.

Int J Oncol. 2016 Aug;49(2):471-8. doi: 10.3892/ijo.2016.3540. Epub 2016 May 27.

29.

Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light-chain amyloidosis.

Gertz MA, Lacy MQ, Dispenzieri A, Buadi FK, Dingli D, Hayman SR, Kumar SK, Leung N, Lust J, Rajkumar SV, Russell SJ, Suman VJ, Le-Rademacher JG, Hogan WJ.

Cancer. 2016 Jul 15;122(14):2197-205. doi: 10.1002/cncr.30051. Epub 2016 May 3.

30.

Status of the Regional Nodal Basin Remains Highly Prognostic in Melanoma Patients with In-Transit Disease.

Gonzalez AB, Jakub JW, Harmsen WS, Suman VJ, Markovic SN.

J Am Coll Surg. 2016 Jul;223(1):77-85.e1. doi: 10.1016/j.jamcollsurg.2016.03.025. Epub 2016 Mar 26.

PMID:
27118347
31.

Window-of-Opportunity Trials in the Preoperative Setting: Insights Into Drug Development for Estrogen Receptor-Positive Breast Cancer.

Goetz MP, Suman VJ.

J Clin Oncol. 2016 Jun 10;34(17):1970-2. doi: 10.1200/JCO.2015.66.2312. Epub 2016 Mar 21. No abstract available.

PMID:
27001589
32.

Immunologic Autograft Engineering and Survival in Non-Hodgkin Lymphoma.

Porrata LF, Burgstaler EA, Winters JL, Jacob EK, Gastineau DA, Suman VJ, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Nevala W, Markovic SN.

Biol Blood Marrow Transplant. 2016 Jun;22(6):1017-1023. doi: 10.1016/j.bbmt.2016.01.024. Epub 2016 Jan 27.

33.

Training High-Volume Melanoma Surgeons to Perform a Novel Minimally Invasive Inguinal Lymphadenectomy: Report of a Prospective Multi-Institutional Trial.

Jakub JW, Terando AM, Sarnaik A, Ariyan CE, Faries MB, Zani S Jr, Neuman HB, Wasif N, Farma JM, Averbook BJ, Bilimoria KY, Allred JB, Suman VJ, Grotz TE, Zendejas B, Wayne JD, Tyler DS.

J Am Coll Surg. 2016 Mar;222(3):253-60. doi: 10.1016/j.jamcollsurg.2015.11.010. Epub 2015 Nov 25.

34.

The ALTERNATE trial: assessing a biomarker driven strategy for the treatment of post-menopausal women with ER+/Her2- invasive breast cancer.

Suman VJ, Ellis MJ, Ma CX.

Chin Clin Oncol. 2015 Sep;4(3):34. doi: 10.3978/j.issn.2304-3865.2015.09.01. Review.

35.

Tumor Cell Adhesion As a Risk Factor for Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma.

Meves A, Nikolova E, Heim JB, Squirewell EJ, Cappel MA, Pittelkow MR, Otley CC, Behrendt N, Saunte DM, Lock-Andersen J, Schenck LA, Weaver AL, Suman VJ.

J Clin Oncol. 2015 Aug 10;33(23):2509-15. doi: 10.1200/JCO.2014.60.7002. Epub 2015 Jul 6.

36.

Reporting of results in DART01/05 GICOR.

Pisansky TM, Suman VJ, Roach M 3rd, Sandler HM.

Lancet Oncol. 2015 Jun;16(6):e258. doi: 10.1016/S1470-2045(15)70243-3. Epub 2015 May 27. No abstract available.

PMID:
26065604
37.

Evaluation of CYP2D6 enzyme activity using a 13C-dextromethorphan breath test in women receiving adjuvant tamoxifen.

Safgren SL, Suman VJ, Kosel ML, Gilbert JA, Buhrow SA, Black JL, Northfelt DW, Modak AS, Rosen D, Ingle JN, Ames MM, Reid JM, Goetz MP.

Pharmacogenet Genomics. 2015 Apr;25(4):157-63. doi: 10.1097/FPC.0000000000000121.

38.

Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance).

Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, Leitch AM, Flippo-Morton TS, Kuerer HM, Bowling M, Hunt KK; Alliance for Clinical Trials in Oncology.

Ann Surg. 2015 Mar;261(3):547-52. doi: 10.1097/SLA.0000000000000551.

39.

Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies.

Goetz MP, Sun JX, Suman VJ, Silva GO, Perou CM, Nakamura Y, Cox NJ, Stephens PJ, Miller VA, Ross JS, Chen D, Safgren SL, Kuffel MJ, Ames MM, Kalari KR, Gomez HL, Gonzalez-Angulo AM, Burgues O, Brauch HB, Ingle JN, Ratain MJ, Yelensky R.

J Natl Cancer Inst. 2014 Dec 8;107(2). pii: dju401. doi: 10.1093/jnci/dju401.

40.

Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.

Perez EA, Romond EH, Suman VJ, Jeong JH, Sledge G, Geyer CE Jr, Martino S, Rastogi P, Gralow J, Swain SM, Winer EP, Colon-Otero G, Davidson NE, Mamounas E, Zujewski JA, Wolmark N.

J Clin Oncol. 2014 Nov 20;32(33):3744-52. doi: 10.1200/JCO.2014.55.5730. Epub 2014 Oct 20.

41.

ERβ1: characterization, prognosis, and evaluation of treatment strategies in ERα-positive and -negative breast cancer.

Reese JM, Suman VJ, Subramaniam M, Wu X, Negron V, Gingery A, Pitel KS, Shah SS, Cunliffe HE, McCullough AE, Pockaj BA, Couch FJ, Olson JE, Reynolds C, Lingle WL, Spelsberg TC, Goetz MP, Ingle JN, Hawse JR.

BMC Cancer. 2014 Oct 7;14:749. doi: 10.1186/1471-2407-14-749.

42.

Evaluation of the Aromatase Inhibition Potential of Freeze-Dried Grape Powder.

Allen SV, Pruthi S, Suman VJ, Hoskin TL, Vachon CM, Ingle JN, Olson JE.

J Diet Suppl. 2015 Dec;12(4):373-382. doi: 10.3109/19390211.2014.952863. Epub 2014 Aug 28.

43.

A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H.

Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME, Rubin J, Karlin N, Sideras K, Morris JC 3rd, McIver B, Hay I, Fatourechi V, Burton JK, Webster KP, Bieber C, Traynor AM, Flynn PJ, Cher Goh B, Isham CR, Harris P, Erlichman C; Endocrine Malignancies Disease Oriented Group, Mayo Clinic Cancer Center, and the Mayo Phase 2 Consortium.

J Clin Endocrinol Metab. 2014 May;99(5):1687-93. doi: 10.1210/jc.2013-3713. Epub 2014 Feb 25.

44.

Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial.

Buzdar AU, Suman VJ, Meric-Bernstam F, Leitch AM, Ellis MJ, Boughey JC, Unzeitig G, Royce M, McCall LM, Ewer MS, Hunt KK; American College of Surgeons Oncology Group investigators.

Lancet Oncol. 2013 Dec;14(13):1317-25. doi: 10.1016/S1470-2045(13)70502-3. Epub 2013 Nov 13.

45.

TGFβ inducible early gene-1 plays an important role in mediating estrogen signaling in the skeleton.

Hawse JR, Pitel KS, Cicek M, Philbrick KA, Gingery A, Peters KD, Syed FA, Ingle JN, Suman VJ, Iwaniec UT, Turner RT, Spelsberg TC, Subramaniam M.

J Bone Miner Res. 2014;29(5):1206-16. doi: 10.1002/jbmr.2142.

46.

Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.

Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, Leitch AM, Kuerer HM, Bowling M, Flippo-Morton TS, Byrd DR, Ollila DW, Julian TB, McLaughlin SA, McCall L, Symmans WF, Le-Petross HT, Haffty BG, Buchholz TA, Nelson H, Hunt KK; Alliance for Clinical Trials in Oncology.

JAMA. 2013 Oct 9;310(14):1455-61. doi: 10.1001/jama.2013.278932.

47.

CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.

Province MA, Goetz MP, Brauch H, Flockhart DA, Hebert JM, Whaley R, Suman VJ, Schroth W, Winter S, Zembutsu H, Mushiroda T, Newman WG, Lee MT, Ambrosone CB, Beckmann MW, Choi JY, Dieudonné AS, Fasching PA, Ferraldeschi R, Gong L, Haschke-Becher E, Howell A, Jordan LB, Hamann U, Kiyotani K, Krippl P, Lambrechts D, Latif A, Langsenlehner U, Lorizio W, Neven P, Nguyen AT, Park BW, Purdie CA, Quinlan P, Renner W, Schmidt M, Schwab M, Shin JG, Stingl JC, Wegman P, Wingren S, Wu AH, Ziv E, Zirpoli G, Thompson AM, Jordan VC, Nakamura Y, Altman RB, Ames MM, Weinshilboum RM, Eichelbaum M, Ingle JN, Klein TE; International Tamoxifen Pharmacogenomics Consortium.

Clin Pharmacol Ther. 2014 Feb;95(2):216-27. doi: 10.1038/clpt.2013.186. Epub 2013 Sep 23.

48.

A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer.

Ma CX, Suman VJ, Goetz M, Haluska P, Moynihan T, Nanda R, Olopade O, Pluard T, Guo Z, Chen HX, Erlichman C, Ellis MJ, Fleming GF.

Breast Cancer Res Treat. 2013 May;139(1):145-53. doi: 10.1007/s10549-013-2528-8. Epub 2013 Apr 19.

49.

Mammographic breast density response to aromatase inhibition.

Vachon CM, Suman VJ, Brandt KR, Kosel ML, Buzdar AU, Olson JE, Wu FF, Flickinger LM, Ursin G, Elliott CR, Shepherd L, Weinshilboum RM, Goss PE, Ingle JN.

Clin Cancer Res. 2013 Apr 15;19(8):2144-53. doi: 10.1158/1078-0432.CCR-12-2789. Epub 2013 Mar 6.

50.

The addition of SPECT/CT lymphoscintigraphy to breast cancer radiation planning spares lymph nodes critical for arm drainage.

Cheville AL, Brinkmann DH, Ward SB, Durski J, Laack NN, Yan E, Schomberg PJ, Garces YI, Suman VJ, Petersen IA.

Int J Radiat Oncol Biol Phys. 2013 Mar 15;85(4):971-7. doi: 10.1016/j.ijrobp.2012.08.025.

PMID:
23452455

Supplemental Content

Loading ...
Support Center